Investment Rating - The report maintains a "Buy" rating for the company, with a target price not specified [6]. Core Insights - The company achieved a revenue of 54.213 billion RMB in 2024, representing a year-on-year growth of 22.48%. The profit attributable to equity holders was 3.862 billion RMB, up 25.20% year-on-year [1]. - The thermal power segment showed stable improvement with a net profit of 1.557 billion RMB, a year-on-year increase of 18.37%. The hydropower segment turned profitable with a net profit of 0.515 billion RMB, while the wind and solar segments reported net profits of 3.183 billion RMB and 1.721 billion RMB, growing 2.14% and 14.43% respectively [2]. - The company's installed capacity reached 49.3909 million kW by the end of 2024, a 9.71% increase year-on-year. Clean energy capacity accounted for 80.12% of the total, with significant growth in wind and solar electricity sales [3]. - The company announced a total dividend of 2.620 billion RMB for 2024, a 59.84% increase year-on-year, with a dividend payout ratio of 67.83% [4]. - The company is actively restructuring its hydropower assets to enhance its position as a leading clean energy platform under the State Power Investment Corporation [5]. - Profit forecasts have been adjusted, with expected net profits of 4.046 billion RMB and 4.531 billion RMB for 2025 and 2026, reflecting year-on-year growth of 20.27% and 11.97% respectively [6]. Summary by Sections Financial Performance - Revenue for 2024 was 54.213 billion RMB, up 22.48% year-on-year [1] - Net profit attributable to equity holders was 3.862 billion RMB, a 25.20% increase [1] - The thermal power segment net profit was 1.557 billion RMB, an 18.37% increase [2] Installed Capacity and Growth - Total installed capacity reached 49.3909 million kW, a 9.71% increase [3] - Clean energy capacity accounted for 80.12% of total installed capacity [3] - Wind electricity sales increased by 41.85% to 26.237 billion kWh, and solar sales grew by 60.37% to 23.425 billion kWh [3] Dividend and Shareholder Returns - Total dividend for 2024 was 2.620 billion RMB, a 59.84% increase [4] - Dividend payout ratio reached 67.83%, up 14.70 percentage points year-on-year [4] Strategic Initiatives - The company is restructuring hydropower assets to strengthen its clean energy platform [5] - Future asset integration opportunities are anticipated within the State Power Investment Corporation [5] Profit Forecasts - Expected net profits for 2025 and 2026 are 4.046 billion RMB and 4.531 billion RMB, with growth rates of 20.27% and 11.97% respectively [6]

Investment Rating - The report does not provide a specific investment rating for the company [1] Core Views - The company has shown steady growth in its vaping segment, while the future of Heat-Not-Burn (HNB) products looks promising, although increased expenditure is impacting short-term profitability [1][2] - The company is expected to face challenges with disposable products due to tightening regulations in various countries, but there is potential for growth in the APV and HNB segments [2][3] - The U.S. market is crucial for the company, with expectations for the launch of new HNB products, which could enhance market share and revenue [3] Financial Performance Summary - In Q1 2025, the company reported a net profit of 192 million yuan, a decrease of 43.4% year-on-year, with total comprehensive income of 208 million yuan, down 32.9% year-on-year [1] - Revenue for 2024 is projected at 11.799 billion yuan, with a growth rate of 6%, and net profit expected to be 1.303 billion yuan, reflecting a decline of 21% year-on-year [5][6] - The company’s adjusted net profit forecasts for 2025, 2026, and 2027 are 1.411 billion yuan, 2.337 billion yuan, and 3.032 billion yuan, respectively, with corresponding P/E ratios of 39.9X, 24.1X, and 18.6X [4][5] Market and Product Insights - The company is positioned as a key supplier for British American Tobacco, which is expanding its HNB product offerings in various markets, including the U.S. [3] - The anticipated launch of the IQOS ILUMA in the U.S. is expected to further pressure traditional cigarette sales, leading to increased focus on HNB product development [3] - The company is expected to benefit from its unique production capabilities and technology, which may help mitigate tariff pressures in the U.S. market [4]

Investment Rating - The report does not provide a specific investment rating for the company [1] Core Views - The company is experiencing steady growth in its vaping segment, while the future of Heat-Not-Burn (HNB) products looks promising, although increased expenses are impacting short-term profitability [1] - The company reported a net profit of 192 million yuan for Q1 2025, a decrease of 43.4% year-on-year, with total comprehensive income of 208 million yuan, down 32.9% year-on-year [1] - The report anticipates a stable revenue stream for Q1, with profit pressure primarily due to increased expenses and a higher tax rate compared to the previous year [1] Summary by Sections Market Environment - The report highlights regulatory changes affecting disposable vaping products in Belgium, France, and the UK, which are expected to pressure the company's performance in this segment [2] - The company is expected to see a recovery in its APV and refillable products overseas, with a trend of year-on-year improvement anticipated [2] HNB Product Development - The company is positioned to benefit from the expansion of HNB products in the US market, with expectations for the launch of new products by PMI [3] - The report notes that the US market is crucial for the company, with projected revenue and adjusted operating profit contributions of 44% and 54%, respectively [3] Financial Projections - The company is projected to achieve adjusted net profits of 1.41 billion yuan in 2025, 2.34 billion yuan in 2026, and 3.03 billion yuan in 2027, with corresponding P/E ratios of 39.9X, 24.1X, and 18.6X [4] - Total revenue is expected to grow from 11.8 billion yuan in 2024 to 17.1 billion yuan in 2027, with a compound annual growth rate of approximately 23% [5] - The report outlines a decrease in net profit for 2024, followed by a recovery in subsequent years, with growth rates of 8% in 2025 and 66% in 2026 [5][7] Key Financial Metrics - The company’s total assets are projected to increase from 27.65 billion yuan in 2024 to 35.85 billion yuan in 2027, indicating a strong growth trajectory [6][7] - The report provides detailed financial metrics, including operating income, net profit, and earnings per share (EPS), with EPS expected to rise from 0.21 yuan in 2024 to 0.49 yuan in 2027 [5][6]

Investment Rating - The investment rating for the company is "Accumulate" [6] Core Views - The company achieved a profit of 1.47 billion yuan in 2024, representing a year-on-year growth of 254%, with a dividend payout ratio of 73% [1] - Revenue for 2024 reached 8.5 billion yuan, an increase of 167.5% year-on-year, aligning with the upper end of the profit forecast [1] - The company's same-store sales growth exceeded 120%, ranking first in revenue and sales efficiency among jewelry brands in mainland China [2] - The gross margin remained stable at 41.2%, while the net profit margin increased significantly to 17.3% [3] - The company is expanding its brand influence and optimizing its product offerings, with plans to open 7 new stores and upgrade 4 existing ones in 2024 [4] Financial Summary - The company forecasts revenues of 17.85 billion yuan in 2025, 24.92 billion yuan in 2026, and 31.12 billion yuan in 2027, with respective year-on-year growth rates of 110%, 40%, and 25% [5] - The projected net profit for 2025 is 3.58 billion yuan, with a year-on-year growth of 143% [5] - The earnings per share (EPS) are expected to be 9.47 yuan in 2024, increasing to 38.63 yuan by 2027 [6]

Investment Rating - The investment rating for the company is "Outperform the Market" [5] Core Views - The company's revenue for 2024 is projected to be 8.624 billion HKD, representing a year-on-year increase of 17.05%. However, the net profit attributable to shareholders is expected to decline by 31.2% to 342 million HKD due to increased dividend withholding tax and fair value changes [8][20] - The increase in uranium prices has significantly boosted the company's pre-tax performance, but the net profit has decreased due to new tax regulations in Kazakhstan and losses from the exchange of shares with Paladin [8][20] - The average sales price of uranium is 75.04 USD/lb U3O8, while the average production cost has risen to 80.80 USD/lb U3O8, reflecting a 4 USD increase year-on-year [12][13] Summary by Sections Financial Performance - In 2024, the company achieved a revenue of 86.24 billion HKD, with a pre-tax profit of 8.14 billion HKD, marking a 48.3% increase year-on-year. However, the net profit attributable to shareholders fell to 342 million HKD, a decrease of 31.2% [8][20] - The company's uranium trading revenue was 86.24 billion HKD, with a segment loss of 0.95 billion HKD. Investment income from other segments was 10.16 billion HKD, with significant contributions from Fission Uranium and Paladin [8][20] Production and Costs - The company self-traded 1,294 tons of uranium in 2024, maintaining production levels from the previous year. The production cost increased to an average of 80.80 USD/lb U3O8 due to rising raw material prices and increased underground resource usage tax [12][13] - The average production cost across mines rose to 24 USD/lb U3O8, primarily due to a supply shortage of sulfuric acid and increased taxes linked to higher sales prices [12][13] Market Trends - The spot price of natural uranium peaked above 100 USD/lb U3O8 at the beginning of 2024 but subsequently declined, with a 27.7% decrease in trading volume year-on-year. Long-term contract prices, however, showed a stable upward trend, rising from 58 USD/lb U3O8 to 80 USD/lb U3O8 [14][20] - The report anticipates a downward adjustment in profit forecasts due to declining spot prices and increased resource usage tax rates, projecting net profits of 635 million HKD, 785 million HKD, and 836 million HKD for 2025-2027 [20]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company plans to acquire 100% equity of Yintech Financial for approximately HKD 108.8 million and purchase its core information system for HKD 18.16 million, marking its entry into overseas finance [1] - The acquisition aims to enhance the company's comprehensive financial service capabilities and expand its overseas financial footprint, particularly in key markets like Hong Kong and the United States [7] - The expected financial performance post-acquisition includes a significant increase in net profit, with projections of CNY 1.293 billion, CNY 1.701 billion, and CNY 2.245 billion for 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 375%, 32%, and 32% [7] Financial Projections - Total revenue is projected to grow from CNY 1.965 billion in 2023 to CNY 4.692 billion by 2027, with a compound annual growth rate (CAGR) of approximately 13.36% [1] - The company's net profit is expected to rebound significantly, with a forecasted increase from CNY 191 million in 2023 to CNY 2.245 billion in 2027 [1] - The earnings per share (EPS) is projected to rise from CNY 0.46 in 2023 to CNY 5.44 by 2027, indicating strong profitability growth [1] Acquisition Rationale - The acquisition of Yintech Financial and its core information system is intended to ensure business continuity, reduce technology dependency risks, and avoid redundant development costs [7] - The phased payment structure for the acquisition is designed to alleviate short-term cash flow pressures, with payments distributed over four stages [7] - The integration of Yintech's licensed operations is expected to strengthen the company's capabilities in cross-border financial services, enhancing its competitive position in the market [7]

Investment Rating - The report maintains a "Buy" rating and adjusts the target price to HKD 1.73 [4][7] Core Views - The company reported a revenue of approximately CNY 6.97 billion for 2024, which is essentially flat year-on-year; the net loss attributable to the parent company is about CNY 451 million, an increase in loss of 3.7% year-on-year; the core net profit attributable to the parent company is approximately CNY 800 million, also flat year-on-year [3][11] Financial Performance Summary - Revenue for 2022 was CNY 7.126 billion, decreasing to CNY 7.010 billion in 2023, and projected to be CNY 6.970 billion in 2024, reflecting a year-on-year decline of 0.6% [6] - The operating profit showed a loss of CNY 730 million in 2022, improving to a loss of CNY 412 million in 2023, but projected to worsen again to a loss of CNY 604 million in 2024 [6] - The net profit attributable to the parent company was a loss of CNY 482 million in 2022, a loss of CNY 435 million in 2023, and is projected to be a loss of CNY 451 million in 2024 [6] - The gross margin is expected to be 21.9% in 2024, down from 23.8% in 2023 [6] Business Segment Performance - The property management business revenue reached CNY 6.38 billion in 2024, a year-on-year increase of 3.6%, accounting for 91.5% of total revenue; community service revenue was CNY 440 million, down 6.5% year-on-year; non-owner value-added services continued to shrink, with revenue decreasing by 61.0% to CNY 147 million [11] - The company’s managed area remained stable at 291 million square meters by the end of 2024, with a year-on-year growth of 7% [11] - The company focused on core cities, with the signing amount in core cities accounting for approximately 98% of total contracts in 2024 [11] Adjustments and Provisions - The company made a provision for bad debts of CNY 1.087 billion in 2024, with a significant portion (CNY 763 million) related to receivables from related parties, which severely impacted profits [11] - After excluding the effects of provisions and amortization, the core net profit attributable to the parent company for 2024 was CNY 800 million, remaining flat year-on-year [11]

医疗美容 可复美延续高增长，可丽金提速，胶原龙头潜力可期 巨子生物（02367.HK） 证券研究报告/公司研究简报 2025 年 04 月 07 日 | 评级： | 买入（首次） | 公司盈利预测及估值 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 指标 | 2023A | | 2024A | 2025E | 2026E | 2027E | | 分析师：郑澄怀 | | 营业收入（百万元） | | 3,526 | 5,539 | 7,056 | 8,893 | 11,021 | | | | 增长率 yoy% | | 48% | 57% | 27% | 26% | 24% | | 执业证书编号：S0740524040004 | | 归母净利润（百万元） | | 1,452 | 2,062 | 2,532 | 3,102 | 3,819 | | Email：zhengch@zts.com.cn | | 增长率 yoy% | | 109% | 42% | 23% | 23% | 23% | | | | 每股收益（ ...

Investment Rating - The report maintains an "Outperform" rating for Ascentage Pharma [2][21]. Core Insights - Ascentage Pharma achieved a revenue of RMB 980 million in 2024, representing a year-on-year growth of 343%, which includes a $100 million option payment from Takeda. The company reported a net loss of RMB 410 million, narrowing by 56.2% year-on-year [3][17]. - The domestic revenue performance of HQP1351 was strong, reaching RMB 240 million, with a significant increase in H2 revenue driven by improved penetration in pharmacies and hospitals [4][18]. - The company completed its U.S. IPO in 2025, raising RMB 967 million, which alleviated cash needs [3][20]. Financial Summary - Revenue projections for FY25-27 are RMB 5.7 billion, RMB 29.9 billion, and RMB 28.0 billion, respectively. Corresponding net profits are projected at RMB -8.4 billion, RMB 12.5 billion, and RMB 9.1 billion [8][21]. - The gross profit margin is expected to remain high, with estimates of 90.1% in FY25 and 98.1% in FY26 [8][14]. - The company’s cash and deposit balance was RMB 1.26 billion at the end of 2024, reflecting a 15.3% increase year-on-year [3][17]. R&D Progress - Ongoing Phase III trials include POLARIS-2 for pretreated CML-CP and POLARIS-3 for SDH-GIST, with plans to submit a Phase III application to the U.S. FDA for POLARIS-1 [5][23]. - The NDA for APG-2575 for R/R CLL/SLL has been accepted by the CDE, with multiple Phase III trials ongoing for various indications [5][23]. Valuation - The target price for Ascentage Pharma is set at HKD 53.1 per share, based on a risk-adjusted discounted cash flow (DCF) model with a WACC of 10.0% and a terminal growth rate of 3.0% [8][21].

Investment Rating - The report maintains an "Outperform" rating for the company [2][16]. Core Views - The company reported a total revenue of RMB 7.47 billion for 2024, a decrease of 6.8% year-on-year, with pharmaceutical sales revenue at RMB 8.62 billion, down 9.0% [12][3]. - The impact of volume-based procurement (VBP) on existing products has largely been digested, with significant sales declines in certain product lines, while innovative products are showing growth [13][4]. - The company has made substantial progress in its innovative drug pipeline, with five products already commercialized and additional assets submitted for NDA approval [14][5]. Financial Performance - Revenue for 2024 was RMB 7.47 billion, down 6.8%, with a gross margin of 72.6%, a decline of 3.6 percentage points due to price cuts from VBP [12][3]. - R&D expenditure increased by 8.9% to RMB 890 million, accounting for 11.9% of total revenue, while selling expenses rose by 6.0% to RMB 2.66 billion [12][3]. - The annual profit was RMB 1.61 billion, down 32.3%, with adjusted net profit at RMB 1.71 billion, down 36.7% year-on-year [12][3]. Sales Breakdown - Cardiovascular and cerebrovascular product line sales were RMB 4.09 billion, down 18.8%, while dermatology and ophthalmology segments showed strong growth [13][4]. - Revenue from three VBP products was RMB 2.69 billion, down 28.8%, indicating that the short-term impact of centralized procurement has largely played out [13][4]. Earnings Forecast and Valuation - Revenue forecasts for 2025 and 2026 have been adjusted to RMB 8.37 billion and RMB 9.44 billion, respectively, reflecting year-on-year growth of 11.5% and 13.3% [15][8]. - The target price is maintained at HKD 9.96 per share, corresponding to a 14x PE for 2025 [16][8].